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We describe the immediate- and longer-term direct medical costs of care for individuals diagnosed with HIV at CD4 counts
<350/mm3 (“late presenters”). We collected and stratiﬁed by initial CD4 count all inpatient, outpatient, and drug costs for all
newly diagnosed patients accessing HIV care within Southern Alberta from 1/1/1995 to 1/1/2010. 59% of new patients were late
presenters. We found signiﬁcantly higher costs for late presenters, especially inpatient costs, during the ﬁrst year after accessing
care. Direct medical costs remained almost twice as high for late presenters in subsequent years compared to patients presenting
with CD4 counts >350/mm3 despite signiﬁcantly their improved CD4 counts. The sustained high cost for late presenters has
implications for recent recommendations for wider routine HIV testing and the earlier initiation of cART. Earlier diagnosis and
treatment, while increasing the immediate expenditures within a population, may produce both direct and indirect cost savings in
the longer term.
1.Introduction
The medical and social aspects of the HIV/AIDS epidemic
have been extensively studied since the ﬁrst cases of AIDS
were described in 1981. The medical cost and economic
burden to society of the HIV/AIDS epidemic have attracted
some but substantially less attention. Early costing studies
in the pre-cART (combination antiretroviral therapy) era
examined the direct medical costs associated with the
morbidity and mortality of AIDS focusing mainly on the
costs of hospitalizations [1–7]. These studies also often
mentioned that the total economic impact of the epidemic
was likely substantially higher than that being measured by
direct medical costs when one included the “indirect costs”
(i.e., costs not directly attributable to the direct medical cost
of HIV/AIDS such as loss of income due to work stoppage)
to family members of those living with HIV/AIDS, and the
opportunity costs incurred by society from the loss of life
from AIDS in a younger, still productive population [8–11].
In the pre and early cART eras, costing studies attempted
to determine the immediate and lifetime direct costs of
HIV disease from the costs associated with various clinically
determined stages such as AIDS or CD4+ lymphocyte count.
They then predicted the duration that any given patient
would be expected to remain in for each one of the stages
using a standardized downward trajectory towards eventual
death and then generated an estimate of lifetime directs costs
for HIV/AIDS [12–17]. This methodology was viewed as
generally being valid as few, if any, eﬀective treatments were
available to slow disease progression.
With the arrival in 1996 and subsequent widespread
implementation of cART, the HIV epidemic changed sig-
niﬁcantly. Morbidity and mortality from HIV decreased
increasing patients’ health, survival, and overall lifespan [18,
19]. The economic burden measured by direct medical costs
has shifted from inpatient costs (i.e., hospitalizations) to
outpatient costs primarily reﬂected as the cost of the ARV
(antiretroviral) drugs, outpatient visits, and laboratory tests
[20–26]. The success of cART is likely even to be greater
than measured in direct costs as it has allowed most patients
to live not only longer and healthier lives, but to maintain
the individual’s productivity thereby decreasing the indirect2 AIDS Research and Treatment
and opportunity costs to family members and to society in
general.
Costing of the HIV epidemic has become far more
complex in the cART era as the disease trajectory is no
longer a predictable decline. Many patients experience a
CD4 increase after starting cART, some maintain stable
CD4 counts while on cART, and some remain with low
CD4 counts but suppressed viremia [27–29]. As such, it
has become increasingly diﬃcult to determine how long any
patient would remain in a particular disease “stage” using
the CD4 count as the stage marker. Costs within any CD4
stratummayvarywidelydependinguponthemixofpatients
with untreated disease or with disease recovering on cART.
This heterogeneity makes this methodology no longer easily
usable on large populations [30–32].
IndividualsinfectedwithHIVmayalsoaccesscareforthe
ﬁrst time at diﬀerent stages of their HIV infection (based on
theirCD4+lymphocytecounts).Thesestagesatpresentation
carry both health and economic implications. The term “late
presenters” was originally used to indicate a person who
initiates HIV care at a “late” stage of their disease or with a
lower CD4 count (i.e., <200/mm3) indicating poorer health
andpoorerhealthoutcomes[33–39].Thesestudiesindicated
that these “late” patients had not only higher mortality and
morbidity than patients presenting “early” but also incurred
substantially more direct medical costs [17, 31, 32]. With
cART, however, mortality and morbidity rates as well as
costs and the distribution of costs have changed for late
presenters. It has also been proposed that the term “late
presenter” be modiﬁed [40] to reﬂect “late for care” with
the CD4 threshold moving to CD4 <350/mm3 and the term
“advanced disease” introduced to reﬂect CD4 <200/mm3.
Theseadjustmentswillmakecomparisonsbetweenhistorical
and current studies diﬃcult unless the deﬁnition of a “late
presenter” is clearly presented.
Using our costing database, we examined in this paper
thecostoflatepresentation(CD4<350/mm3)overa15-year
period describing past and current trends. We determined
the cost of care of both late and “early” presenters (i.e.,
patients who access initial HIV care with CD4 counts
>350/mm3) over time comparing costs after accessing HIV
care. We discuss the impact of late presentation on current
recommendations for more widespread and routine HIV
screening and testing, and on the proposed “test and treat”
strategies under discussion. Late presentation has not only
clinical and public health implications within the HIV
epidemic but also has ﬁnancial and costing implications.
2. Methods
The Southern Alberta Clinic Cohort (SAC) includes all HIV-
infected patients receiving HIV care and living within south-
ern Alberta, Canada. Patients are automatically included in
the cohort when they initiate HIV care within a centralised
outpatient program. SAC provides exclusive, comprehensive
interdisciplinary care to all HIV patients living in southern
Alberta including pharmaceuticals, outpatients, and labo-
ratory tests. All individuals testing positive for HIV are
referred to SAC located in Calgary, Alberta. Over 90%
of patients reside within the immediate Calgary region.
Inpatient services are provided in one of 3 local hospitals.
Administrative data including demographic, clinical
characteristics as well as the direct cost of care are collected
on all individuals on a routine basis during every clinical
contact. Use of this administrative data was approved by
the University Conjoint Medical committee on medical
bioethics.
We include all newly infected HIV individuals diagnosed
within the region who accessed their initial HIV treatment
at SAC (“locally diagnosed patients”). Individuals who were
diagnosed elsewhere were included if they were initiated care
within 6 months of their diagnosis and had not accessed
HIV elsewhere prior to their 1st SAC visit. We include all
individualsinitiatingcarebetween1Jan1995and1Jan2010.
To be included, patients must have had at least one regular
clinicvisit.Patientswerefolloweduntiltheymoved,werelost
to followed, died or until 1 April 2010.
Weusethedeﬁnitionof“latepresenters”asthosepatients
who initiated care with a CD4 count <350/mm3 although
we also subdivide this group by CD4 count > or < than
200/mm3 for comparisons with earlier uses of the term
“late presenters.” We collected the patient’s gender, age at
clinic visit, risk factor (MSM, MSW, IVDU, other) and self-
reported ethnicity (Caucasian/non-Caucasian) at the initial
visit. We recorded the patient’s initial CD4 count taken
within 30 days of the initial visit and any recorded AIDS
deﬁning condition at diagnosis.
The Southern Alberta Clinic Cohort has been con-
tinuously tracking the direct cost of care for all HIV-
infected patients followed at the regionalized Southern
AlbertaClinic.SACestablisheda“costingsearchengine”that
routinely captures all the direct costs of care including ARV
(antiretroviral)andnon-ARVdrugcosts,alloutpatientclinic
visits including laboratory texts and referrals to non-HIV
specialists, and the cost of inpatient (i.e., hospitalizations)
visits for both HIV and non-HIV-related admissions. Costs
arecollectedperpatient,perdemographicpopulation,orper
a number of other variables including the CD4 status of the
individual patient.
For this study, the direct costs of care were collected
between 1/1/1995 and 12/31/2009. Costs were collected from
the original costing source or agency using a methodology
previously described [16]. Brieﬂy, we collected the direct
costs of drugs (antiretroviral (ARV) and nonantiretroviral
drugs), outpatient clinical care (including physician and
laboratory costs), and inpatient (hospital) care. ARV and
non-ARV drug costs, lab utilization, and outpatient care
costs were derived directly from the SAC pharmacy, Calgary
Laboratory Services, and the SAC-costing database whereas
inpatient costs (i.e., unit service costs) were supplied by
the regional health service providers. The unit costs used
are market values charged to the regional payer (Alberta
Health Services). All costs were obtained directly from the
costing agencies and reported in Canadian dollars adjusted
for inﬂation to 2009.
Annual costs for patients who initiate HIV care at SAC
are reported from the date of initiating year to DecemberAIDS Research and Treatment 3
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Figure 1: Proportions of newly diagnosed HIV patients accessing care with CD4 counts <200/mm3 (“advanced disease”) and/or <350/mm3
(“late presenters”).
Table 1: Demographic and clinical characteristics of patients
followed within the Southern Alberta Clinic Cohort from 1995
to 2009 (selected years only) accessing initial HIV care with CD4
counts <350/mm3 (“late presenters”).
1995 2000 2005 2009
Total no. of late
presenters (%) 47 (67) 34 (56) 45 (56) 67 (71)
Male (%) 42 (89) 39 (87) 36 (80) 49 (73)
M e d i a n a g e ( y r s ) 3 03 23 33 4
[IQR] [26–37] [27–39] [27–40] [28–41]
Risk factor
MSM (%) 31 (66) 20 (58) 24 (54) 30 (45)
Heterosexual 8 (17) 5 (16) 11 (24) 29 (43)
IVDU 7 (15) 7 (22) 9 (20) 7 (10)
Other 1 (2) 2 (4) 1 (2) 1 (2)
Caucasian (%) 37 (79) 24 (70) 25 (55) 32 (48)
Median initial CD4 123 55 159 193
[IQR] [36–211] [10–214] [80–261] [63–263]
31st of that particular year. Costs are then adjusted as
mean cost per patient per month (PPPM) in 2009 Cdn$
over the time followed in that year, and cumulatively for
patients initiating care ±350/mm3. The annual cost for “late
presenters” is reported as a proportion of all costs for newly
diagnosed HIV patients accessing care for the ﬁrst time.
Long-term or “lifetime” costs are determined from the date
of initiating HIV care to the date they moved, were LTFU
(lost to followup), died, or 4/1/2010 and, are reported as
mean PPPM or PPPY (per patient per year) costs.
Health care utilization data is based on number of
clinic visits, laboratory tests, visits to HIV, and non-HIV
physicians(i.e.,outpatientvisits),andthenumberofhospital
admissions (inpatient visits/length of stay (LOS)). Admin-
istrative data were obtained directly from the SAC database
and hospitalization admission records. Visits for physicians
for non-HIV related conditions were self reported by the
patients and may be underreported. Clinical protocols on
recommended frequency of clinic visits, ART options, and
laboratory testing algorithms for patients remained stable
during the study period.
We compare the PPPM cost of care for late presenters
initiating care at SAC to that of early presenters over the
same time period and under the same clinical protocols. We
provide descriptive statistics (i.e., mean, standard deviations,
medians) to describe the data. We use Student t-tests for
normally distributed data and Mann Whitney U-test for non
normally distributed variables to compare the populations.
Chi-square tests were used to compare proportions. P<. 05
was set for the level of signiﬁcance.
3. Results
The demographic and clinical characteristics of late pre-
senters are listed in Table 1. Between 1995 and 2010, 59%
of all locally diagnosed patients initiated care with a CD4
<350/mm3 (36% with CD4 counts <200/mm3) as shown in
Figure 1. We found a change in the demographics of late
presenters during this period. In 1995, 89% were male, 66%
were MSM (men who have sex with men), and 79% were
Caucasian; in 2009, 73% were male, 45% MSM (43% were
MSW), and 48% were Caucasian. The median CD4 count
for late presenters was 149/mm3 (IQR [47-253]); 26% of
late presenters had an AIDS deﬁning condition at time of
accessing care. 9.6% of late presenters died within 60 months
of accessing care.
Overthepast15years,locallydiagnosed“latepresenters”
account for 56% of the total patient months followed at SAC
compared to 44% for early presenters (>350/mm3); however,
theyaccountfor>68%ofallcosts(Figure 2(a)).Overall,70%
of all drug costs (69% of ARV drug costs, 84% of all non-
ARV drug costs), 61% of all outpatient costs, and 64% of
hospital costs (92% of HIV-related hospital costs and 51%
of non-HIV-related hospital costs) were attributable to late
presenters (Figure 2(b)).4 AIDS Research and Treatment
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Figure 2: (a) Proportional costs of direct medical care with for newly diagnosed HIV patients accessing care from 1995 to 2010, (b)
catergorized by cost category.
The proportional annual cost of care for late presenters
versus early presenters for the year the person was diagnosed
is presented in Figure 3. With the increased use of cART
and with the trend at initiating cART at higher CD4 counts,
we found that the proportional costs for late presenters
increased substantially over the past 15 years—from 60%
between 1995 and 1999 to over 75% between 2000 and 2009.
Inpatient costs account for nearly two thirds (i.e., 64%) of all
the costs incurred during the ﬁrst year after accessing HIV
for late presenters.
Patients who present late continue to cost more despite
a recovery in their health in subsequent years beyond their
initial year of diagnosis (Figure 4). Overall, late presenters
costameanof$1419±$378permonth($17,028±$5,031per
year)comparedto$914±$452 permonth($10,968±$5,677
per year) for early presenters. Although there is yearly vari-
ation, mean PPPM costs remain substantially higher every
year throughout the past 15 years. This substantial diﬀerence
isalsoseenforpatientswhohavebeencontinuouslyfollowed
at SAC from initial time of access care to the end of 2009.
The mean initial CD4 count for late presenters was 122/mm3
at ﬁrst visit and 437/mm3 at their latest CD4 count in 2009
compared to 470/mm3 and 566/mm3,r e s p e c t i v e l y ,f o re a r l y
presenters yet mean PPPM cost for these “late presenters” for
the year 2009 remained almost twice as high (i.e., $1477 ±
$402 versus $896 ± $366) despite signiﬁcant improvements
in CD4 counts.
4. Discussion
We have documented that over the past 15 years the
direct cost of care has remained signiﬁcantly higher (>50%)
for HIV-infected patients who present with a CD4 count
<350/mm3. These costs are not exclusively derived from the
use of cART but reﬂect all direct medical costs. We have
also shown that these increased direct costs are sustained
beyond the initial year of care after presentation and persist
despite CD4-rebound and -improved health. Late presenters
continue after presentation to use not just more cART and
outpatient care but more inpatient care, and, more non-ARV
drugs. These costs may not only reﬂect lifelong legacy costs
of the residual morbidities from some AIDS conditions but
alsomayreﬂectthecostsofcomplexsocialandmedicalissues
that contributed to late presentation (e.g. denial, psychiatric
illness, substance use). The rate of hospital admissions in
late presenters is higher for both HIV and non-HIV-related
conditions both at initial presentation and in subsequent
years suggestive of the importance of legacy morbidityAIDS Research and Treatment 5
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Figure 3: Proportions of the total direct medical costs incurred by “late presenters” (<350/mm3) as a percentage of all direct medical costs
for newly diagnosed HIV patients accessing care.
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Figure 4: Mean cumulative PPPM (per patient per month) total cost of care for HIV patients accessing care in the year listed and followed
until the patient moved, died, or 12/31/2009 in 2009 Cdn$.
and comorbidities. Fleishman et al. [32] also documented
substantially higher continuing direct medical costs in the
United States for late entrants to HIV care even after 7 to
8 years in care. They state that earlier entry into HIV care
at relatively less costly disease stages could reduce aggregate
expenditures. Our ﬁndings concur.
Thecenterfordiseasecontrol[41]recommendedin2006
more widespread and routine HIV testing as a means to
detect more of the 20% to 33% of individuals who currently
unaware they are HIV infected. The ﬁndings from this and
other similar costing studies, carry implications with regard
to assessing the economic impact of these recommendations
as well as for the associated increased cART use for patients
successfully engaged in HIV care.
It is anticipated that a substantial number of individuals
identifying earlier with lower CD4 counts through this
wider testing process will successfully engage in care, receive
cART, decrease their infectivity (and the rate of secondary
infections),andimprovetheirownhealth.Thecostsofwider
testing and the increased use of cART may be defrayed by
decreasing the substantial and sustained direct medical costs
from later presentation, the indirect costs to family from an
avoidable illness (i.e., presentation with HIV/AIDS), and the
opportunity costs to society by minimising lost productivity
and reducing secondary infections [42, 43].
It is argued that the largest societal cost impact of earlier
and more widespread detection of HIV and engagement to
care will be the public health eﬀect of “infections prevented.”
Proponents of the “test and treat” strategies for HIV
preventionstatedthatexpandedtestingandearliertreatment
couldmarkedlydecreaseongoingHIVinfectionand,intime,
stem the HIV epidemic [44–46]. Those on treatment will
have decreased viral loads and be less infectious and, in
principle, should decrease to some degree new infections.
The precise reduction in new infections from such a strategy
within a population remains highly speculative along with
its predicted savings both in actual costs and in reduced HIV
transmission [47–49].6 AIDS Research and Treatment
On a population level beyond the costs of wider testing,
the cost of HIV care will increase as the number of
individuals diagnosed with HIV and on treatment will
increase. We have previously shown that the overall cost
of care for HIV-infected individuals will increase within a
population as more individuals are detected and begin to
access HIV care and ARV drugs [50]. We estimated that
wider screening and initiated HIV care would increase HIV
costs by 21 to 28% if over half of the currently unidentiﬁed
individuals with HIV infection were identiﬁed and accessed
care. However, on an individual basis, patients who access
care at a higher CD4 count have much lower cost PPPM over
the course of their condition compared to individuals who
access care at lower CD4 counts. We have shown how costs
remain high over at least 7 years or more of followup despite
improved health. As both early and late presenters now live
longer and require sustained treatment and management of
their condition, the diﬀerence in the cost PPPM between
these groups will continue to be disproportional.
Our study, while comprehensive, does have limitations.
Many factors including the ease and availability of accessing
care, the composition of the HIV community, the location
of the HIV care site or sites, the cost of direct or indirect
health care within the community, the use and preference
by ARV’s by health care providers, and other aspects of
care delivery may inﬂuence mean cost PPPM over time
and between geographic locations. Collection of costing
data itself may increase or decrease actual costing estimates.
We have attempted to reduce many of the factors by
concentratingononlythosepatientsdiagnosedandaccessing
care at a centralized care center within a deﬁned geographic
population over the course of 15 years in which there was a
continuity in clinic protocols and management philosophy
driven by international guidelines. Costing collection and
the methodologies applied have remained the same over the
study period. Although the actual costs of ARV medicine,
outpatient and inpatient care may be higher or lower than
other centers due to diﬀerences in health care systems across
and inside any country, the proportional diﬀerences we
identiﬁed are remarkably similar to those reported by others
in costing studies, and, thus, the analysis and discussion
should be widely applicable. Our study also only reports
on costs in a developed country and as such is not directly
relevant to costing studies in developing nations where
clinical, demographic, and economic issues are signiﬁcantly
diﬀerent [51–54], at least to a degree. The underlying aspects
and costing principles presented in our study can be applied
to other situations albeit with diﬀering cost estimates.
Two other considerations will need to be addressed in
future costing studies. More and more ARV drugs will be
coming oﬀ patent in the near future and will be avail-
able in generic form. This most likely will directly or
indirectly reduce the cost of ARV drugs and regimens and
should reduce long-term costs of care for HIV-infected
individuals. How much and how quickly these costs change
will increasingly make future costing projections less precise.
Another important aspect to be addressed is the cost savings
in indirect costs and opportunity costs from cART therapy.
Improving the health of HIV patients and increasing their
longevity not only is beneﬁcial to the patient’s health but
its major impact is likely in minimising indirect cost to
patientsfamilyforcaringandinreducingopportunitycostto
society form lost productivity. Future studies need to explore
such issues to further measure the economic impact of early
identiﬁcation and treatment with cART.
5. Conclusion
HIV/AIDS has been and continues to be an expensive
disease to manage. Early detection and treatment of the HIV
infection has been shown to produce very positive clinical
and public health eﬀects; however, at the same time, direct
medical care costs increase as patients initiate cART earlier
and over longer-time periods. Increased initial costs can be
defrayed over time by more stable and lower costs of care
as health improves. Many costly hospitalizations may be
avoided with proper disease management. Earlier detection
and access to HIV care may also reduce indirect costs as
patients maintain productive lifestyles to the best of their
abilities thus also reducing societal costs. The high initial and
sustained costs of late presentation in HIV disease is a factor
in discussions on more widespread testing and treatment of
HIV disease.
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